Article Sidebar
Published:
Nov 24, 2016Article Details
Copyright remains in the Author’s name. The work is licensed under a Creative Commons Attribution - Noncommercial Works License. Authors are required to complete and sign an Author Agreement form that outlines Author and Publisher rights and terms of publication. The Agreement form should be uploaded along with other submissions files and any submission will be considered incomplete without it [forthcoming].
Material submitted for publication in the SAMJ is accepted provided it has not been published or submitted for publication elsewhere. Please inform the editorial team if the main findings of your paper have been presented at a conference and published in abstract form, to avoid copyright infringement. The SAMJ does not hold itself responsible for statements made by the authors.
Previously published images
If an image/figure has been previously published, permission to reproduce or alter it must be obtained by the authors from the original publisher and the figure legend must give full credit to the original source. This credit should be accompanied by a letter indicating that permission to reproduce the image has been granted to the author/s. This letter should be uploaded as a supplementary file during submission.
Main Article Content
Management of chronic hepatitis Band C
Abstract
Chronic viral hepatitis caused by hepatitis B, C or 0 may lead to cirrhosis, hepatocellular failure and hepatocellular carcinoma. The morbidity of these diseases has necessitated a prolonged search for effective therapy. Although many antiviral compounds have been evaluated for the treatment of chronic viral hepatitis, few have achieved clinical applicability. Alpha-interferon has been widely studied, and remains the mainstay of treatment. A number of other cytokines, including thymosin, are being evaluated. Nucleoside analogues, alone or in combination with alphainterferon, may prove useful adjuncts to the treatment of chronic hepatitis Band C.
